A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
Status: | Withdrawn |
---|---|
Conditions: | Diabetes, Diabetes, Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 2 - 75 |
Updated: | 8/22/2018 |
Start Date: | July 2018 |
End Date: | December 2018 |
The purpose of this study is to demonstrate the performance of the Harmony 1 Sensor in
subjects age 2 - 75 years
subjects age 2 - 75 years
This study is a multi-center, randomized, prospective single-sample correlational design
without controls. A total of up to 310 previously-diagnosed type 1 or 2 diabetes subjects
will be enrolled in order to have 160 subjects complete frequent sample testing at up to 17
centers. Subjects will wear Harmony 1 sensors used with the Guardian Mobile application.
without controls. A total of up to 310 previously-diagnosed type 1 or 2 diabetes subjects
will be enrolled in order to have 160 subjects complete frequent sample testing at up to 17
centers. Subjects will wear Harmony 1 sensors used with the Guardian Mobile application.
Inclusion Criteria:
- Subject is 2-75 years of age at time of screening
- A clinical diagnosis of type 1 or 2 diabetes for a minimum of 12 months duration as
determined via medical record or source documentation by an individual qualified to
make a medical diagnosis
- Adequate venous access as assessed by investigator or appropriate staff
- Subjects participating in the high and low glucose challenges must have an established
insulin carbohydrate ratio(s) and insulin sensitivity ratio. (The term "established"
refers to a ratio that has been previously defined and tested prior to screening
visit). Subjects without established ratios may participate under observation only.
Exclusion Criteria:
- Subject will not tolerate tape adhesive in the area of Harmony 1 Sensor placement as
assessed by qualified individuals
- Subject has any unresolved adverse skin condition in the area of Harmony 1 Sensor or
device placement (e.g., psoriasis, rash, Staphylococcus infection)
- Subject is actively participating in an investigational study (drug or device) wherein
they have received treatment from an investigational study (drug or device) in the
last 2 weeks
- Subject is female and has a positive pregnancy screening test
- Females of child bearing age and who are sexually active should be excluded if they
are not using a form of contraception deemed reliable by investigator
- Subject is female and plans to become pregnant during the course of the study
- Subject has had a hypoglycemic seizure within the past 6 months
- Subject has had hypoglycemia resulting in loss of consciousness within the past 6
months prior to screening visit
- Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months
prior to screening visit.
- Subject has a history of a seizure disorder
- Subject has central nervous system or cardiac disorder resulting in syncope
- Subject has a history of myocardial infarction, unstable angina, coronary artery
bypass surgery, coronary artery stenting, transient ischemic attack (TIA),
cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm
disturbances or thromboembolic disease
- Subject has a hematocrit (Hct) lower than the normal reference range
- Subject has a history of adrenal insufficiency
We found this trial at
8
sites
Renton, Washington 98057
Principal Investigator: Ronald Brazg, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Aurora, Colorado 80010
Principal Investigator: Robert Slover, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Walnut creek, California 94598
Principal Investigator: Mark Christiansen, MD
Click here to add this to my saved trials